Partial pharmacovigilance outsourcing offers biopharmaceutical companies a flexible way to stay compliant without committing to a full-service model. By outsourcing high-volume pharmacovigilance activities they can’t efficiently manage in-house, such as case processing, aggregate safety report writing, local QPPVs, and global and local literature screening, mid- to large-sized biopharma companies maintain oversight while scaling resources as needed.
This approach has become especially valuable for commercial-stage biopharma companies managing post-marketing safety activities and expanding into new regions. Rather than overbuilding internal teams or relying entirely on external vendors, partial outsourcing provides targeted support where it matters most.
In this article, we explore how the model works, where it delivers the most value, and how to structure it for long-term success, especially for teams optimizing or scaling established pharmacovigilance systems.
Looking for a broader strategy on how centralized PV systems operate across global markets? Read our cornerstone guide on centralized pharmacovigilance.
What is partial pharmacovigilance outsourcing?
So, partial pharmacovigilance outsourcing is a flexible model where mid- to large-sized biopharma companies delegate selected pharmacovigilance (PV) activities to an external service provider, while maintaining overall oversight and key responsibilities in-house. This allows companies to choose exactly which functions to outsource, which is often based on internal capabilities, regulatory exposure, and product lifecycle stage.
This model is especially common among commercial-stage biopharma companies managing ongoing post-marketing pharmacovigilance requirements. Even in established organizations, internal PV teams may not always have the capacity or regional coverage required to manage all safety activities efficiently. Therefore, partial outsourcing bridges that gap by allowing biopharma teams to remain the system owner, while leaning on experienced partners for execution.
For example, a sponsor might:
- Keep signal detection and global oversight with the internal safety lead
- Outsource case processing and ICSR submission to a pharmacovigilance service provider
- Appoint regional PV partners for QPPV coverage or local literature screening in specific markets
This approach preserves operational flexibility and avoids over-investing in functions that are best handled by specialized external partners.
Why biopharma companies choose partial pharmacovigilance outsourcing?
As previously mentioned, partial pharmacovigilance outsourcing gives companies targeted support without the cost or complexity of unnecessarily expanding internal PV functions. But its added value lies in how well it adapts to the specific pressures these companies face.
In particular, this model proves most valuable in three high-stakes scenarios:
- Managing high-volume post-marketing safety workloads
Post-marketing environments require continuous case intake, processing, and regulatory reporting. A partial model provides access to scalable case processing, validated systems, and experienced PV professionals without overburdening internal teams.
- Maintaining inspection readiness and audit preparedness
Regulatory authorities expect audit-ready pharmacovigilance systems at all times across marketed products. Partial outsourcing supports consistent compliance, high-quality documentation, and sustained inspection readiness.
- Entering new regions with local PV obligations
Expansion into the EU, CIS, or MENA requires national QPPV requirements, language-specific literature reviews, and regional timelines. Regional PV partners can handle these country-level tasks, reducing the burden on central teams.
Which functions to outsource in a partial pharmacovigilance model?
Partial pharmacovigilance outsourcing only works if it’s structured deliberately. Here’s how that typically breaks down for mid- to large-sized commercial biopharma companies:
Commonly outsourced functions
- Case processing & ICSR submission
One of the most resource-intensive PV tasks. A pharmacovigilance service provider can handle intake, triage, data entry, narrative writing, and electronic submissions using validated systems.
- Local QPPVs and national contact points
Essential in regions like the EU, CIS, or MENA, where in-country representation is required. Regional PV partners can act as QPPVs or local safety officers, ensuring compliance with local timelines and formats.
- Literature screening
Regulatory authorities expect ongoing monitoring of national and global scientific literature. Outsourcing this task to a vendor with native language expertise ensures comprehensive coverage without overburdening internal teams.
- Periodic reports (PSURs, DSURs)
These require structured formatting and precise timelines. Outsourcing ensures consistency and avoids bottlenecks during reporting cycles.
Strategic pharmacovigilance functions to retain or closely oversee
- Signal detection & risk evaluation
These are strategic activities that benefit from deep product knowledge. When internal expertise is available, biopharma teams could focus on leading these activities to ensure context-driven decision-making, while external partners can still support data processing and analysis.
- PV governance & oversight
Even in a partial outsourcing model, the MAH remains legally responsible for pharmacovigilance. Internal teams should maintain oversight of SOPs, vendor management, and audit readiness, while external providers can support execution and documentation as needed.
- Cross-functional safety strategy
Interactions with regulatory, medical, and commercial teams require integrated thinking. When internal capabilities exist, maintaining safety leadership within the organization helps ensure alignment with broader business and product strategy, while external experts may contribute specialized input.
How to scale your model as your pipeline grows?
One of the biggest advantages of partial pharmacovigilance outsourcing is its ability to scale as your team evolves. As product portfolios expand, geographic presence increases, and safety reporting becomes more complex, your outsourcing model should scale in step.
A good pharmacovigilance service provider helps you expand your PV system deliberately, without overwhelming internal teams. This means:
- Expanding literature monitoring to new languages and markets
- Adding local QPPVs in additional countries as needed
- Shifting from case-by-case reporting to more structured signal management
- Upgrading SOPs and documentation for inspection readiness
The model matures with you. Done right, partial outsourcing isn’t a temporary fix but more of a strategic framework that supports biopharma companies in maintaining efficient and compliant post-marketing pharmacovigilance operations.
Conclusion
All in all, partial pharmacovigilance outsourcing offers biopharma companies a practical way to stay compliant, scale safely, and maintain control. The key is knowing which functions to outsource and which to keep in-house.
At Biomapas, we deliver both partial and end-to-end pharmacovigilance outsourcing solutions, designed to scale with your organization. Our team works as an extension of your safety function, offering flexible, region-specific support across the EU, CIS, MENA, and beyond. Whether you’re managing post-marketing safety activities, expanding geographically, or addressing regulatory demands, we help you build a PV system that’s inspection-ready without being overbuilt.
Need a partner who knows how to scale with you?
Contact Biomapas to learn how partial outsourcing can support your safety strategy, now and as you grow.
